Avalyn starts Phase 1 trial of dual-combination inhaled drug AP03
The biotech reported Q3 2026 results, with topline data across all three pulmonary fibrosis programs expected in 2027 and cash extending into 2029.
SEC filing
2 stories
The biotech reported Q3 2026 results, with topline data across all three pulmonary fibrosis programs expected in 2027 and cash extending into 2029.
SEC filing
The former FDA official and regulatory consultant joins as a Class II director effective September 15, 2026.
SEC filing